News & Updates

Show Multimedia Only
Obesity med cessation more likely after RYGB than sleeve gastrectomy

Obesity med cessation more likely after RYGB than sleeve gastrectomy

15 Apr 2022 byRoshini Claire Anthony

Patients who are on obesity-related medications before undergoing bariatric surgery may be more likely to discontinue their medications and less likely to restart them after undergoing Roux-en-Y gastric bypass (RYGB) than laparoscopic sleeve gastrectomy (LSG), a recent study has shown.

Obesity med cessation more likely after RYGB than sleeve gastrectomy

15 Apr 2022
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

14 Apr 2022
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

12 Apr 2022 byJairia Dela Cruz

Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab

12 Apr 2022